MA41152A - Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques - Google Patents

Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques

Info

Publication number
MA41152A
MA41152A MA041152A MA41152A MA41152A MA 41152 A MA41152 A MA 41152A MA 041152 A MA041152 A MA 041152A MA 41152 A MA41152 A MA 41152A MA 41152 A MA41152 A MA 41152A
Authority
MA
Morocco
Prior art keywords
particles
phenylephrine resinate
phenylephrine
pharmaceutical formulations
resinate
Prior art date
Application number
MA041152A
Other languages
English (en)
Inventor
Vincent W Chen
Edward A Koch
Der-Yang Lee
Shun-Por Li
Joel Waldman
Original Assignee
Johnson & Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc filed Critical Johnson & Johnson Consumer Inc
Publication of MA41152A publication Critical patent/MA41152A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA041152A 2014-12-12 2015-12-10 Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques MA41152A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462091096P 2014-12-12 2014-12-12

Publications (1)

Publication Number Publication Date
MA41152A true MA41152A (fr) 2017-10-17

Family

ID=55130033

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041152A MA41152A (fr) 2014-12-12 2015-12-10 Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques

Country Status (13)

Country Link
US (2) US20160166518A1 (fr)
EP (1) EP3229787A1 (fr)
JP (2) JP6720174B2 (fr)
KR (1) KR20170095939A (fr)
CN (2) CN115068425A (fr)
AU (1) AU2015360386B2 (fr)
BR (1) BR112017012400A8 (fr)
CA (1) CA2969473A1 (fr)
HK (1) HK1245155A1 (fr)
MA (1) MA41152A (fr)
MX (1) MX382918B (fr)
RU (1) RU2727204C2 (fr)
WO (1) WO2016094751A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3522890A4 (fr) 2016-10-10 2020-06-03 Rhodes Pharmaceuticals L.P. Compositions pharmaceutiques à base de résinate et leurs procédés de fabrication et d'utilisation
IL311303B2 (en) 2017-10-09 2026-05-01 Rhodes Pharmaceuticals Lp Medicinal resin components and methods for their production and use
CN113384521B (zh) * 2020-03-12 2023-03-28 中国科学院上海高等研究院 一种快速增溶去甲肾上腺素水溶液且有效抑制样品氧化的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
AU736308B2 (en) 1996-12-20 2001-07-26 Warner-Lambert Company Llc Antitussive drugs delivered by ion exchange resins
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US8343546B2 (en) 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
ATE536867T1 (de) * 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
US20070231387A1 (en) * 2006-04-04 2007-10-04 Luigi Levi Film-coated solid dosage forms
MX2008015358A (es) 2006-06-01 2009-03-06 Schering Corp Composiciones farmaceuticas para liberacion sostenida de fenilefrina.
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
BRPI0719021A2 (pt) 2006-11-21 2013-12-17 Mcneil-Ppc, Inc. Suspensões analgésicas de liberação modificada.
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
RU2011102777A (ru) 2008-06-26 2012-08-10 МакНЕЙЛ-ППС, ИНК. (US) Частицы с покрытием, содержащие фармацевтически активные агенты
WO2010115015A1 (fr) * 2009-04-03 2010-10-07 Coating Place, Inc. Composition médicamenteuse pharmaceutique à libération modifiée
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
EP2726066B1 (fr) * 2011-06-28 2021-03-31 Neos Therapeutics, LP Formes posologiques de l'amphetamine pour administration orale
HK1203162A1 (en) 2012-02-07 2015-10-23 麦克内尔-Ppc股份有限公司 Rapidly disintegrating coated tablets
US20140271891A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles and use thereof in pharmaceutical formulations
US20140271892A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc

Also Published As

Publication number Publication date
WO2016094751A1 (fr) 2016-06-16
HK1245155A1 (zh) 2018-08-24
AU2015360386A1 (en) 2017-06-15
US20160166518A1 (en) 2016-06-16
BR112017012400A2 (pt) 2018-04-24
RU2017124229A (ru) 2019-01-15
RU2727204C2 (ru) 2020-07-21
AU2015360386B2 (en) 2021-02-25
JP2017537132A (ja) 2017-12-14
JP7016907B2 (ja) 2022-02-07
RU2017124229A3 (fr) 2019-04-16
JP2020125344A (ja) 2020-08-20
US20210330614A1 (en) 2021-10-28
MX382918B (es) 2025-03-13
CA2969473A1 (fr) 2016-06-16
KR20170095939A (ko) 2017-08-23
MX2017007596A (es) 2018-03-09
BR112017012400A8 (pt) 2022-08-09
CN115068425A (zh) 2022-09-20
CN106999433A (zh) 2017-08-01
JP6720174B2 (ja) 2020-07-08
EP3229787A1 (fr) 2017-10-18

Similar Documents

Publication Publication Date Title
HUE049341T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
IL261989A (en) A pharmaceutical formulation of palbociclib and a preparation method thereof
HUE053309T2 (hu) Új sók és gyógyászati készítmények gyulladásos betegségek kezelésére
BR112016026205A2 (pt) Moduladores de entrançamento de gene smn2, seu uso e seu processo de preparação, e composições farmacêuticas
PL3177329T3 (pl) Układ do natychmiastowego uwalniania substancji aktywnych
EP3679924C0 (fr) Formulation comprenant des particules
EP3476386C0 (fr) Composition pharmaceutique liquide
IL259246A (en) Compositions of therapeutic substances, methods and uses thereof
MA42196A (fr) Particules de fumarate de diméthyle et leurs compositions pharmaceutiques
HUE055209T2 (hu) Terápiásan aktív vegyületek gyógyszerészeti készítményei
PL3236935T3 (pl) Farmaceutyczna postać dawkowania do zastosowania na błony śluzowe
PL3881833T3 (pl) Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
EP3429589A4 (fr) Composition pharmaceutique du nilotinib
SI3102185T1 (sl) Nanosuspenzija naravnih materialov in postopek priprave le-te
PL3452100T3 (pl) Nośniki farmaceutyczne zawierające mirna do zastosowania w leczeniu chorób zwłókieniowych spowodowanych hiperglikemią
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
HUE041438T2 (hu) Eljárás optikailag aktív izoxazolin vegyületek elõállítására
IL244881A0 (en) Hiv treatment formulation of atazanavir and cobicistat
PL3145508T3 (pl) Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
PT2957280T (pt) Composição farmacêutica sólida de citisina e processo para a sua preparação
FR3012146B1 (fr) Particules organiques, procede de preparation et utilisation dans la fabrication du papier
IL248012A0 (en) Porous materials containing compounds including pharmaceutically active species
EP2586463A4 (fr) Particules multimères pharmaceutiques et leur procédé de fabrication
PL3215181T3 (pl) Sposoby wytwarzania kompozycji o ulepszonym profilu bezpieczeństwa zawierających pankreatynę i kompozycje odpowiednie do zastosowania farmaceutycznego
EP2895168A4 (fr) Formulations pharmaceutiques de tétrandrine et procédé associé